Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer.

A new interesting article has been published in Invest New Drugs. 2019 May 23. doi: 10.1007/s10637-019-00785-5. and titled:

Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer.

Authors of this article are:

Liu QH, Yong HM, Zhuang QX, Zhang XP, Hou PF, Chen YS, Zhu MH, Bai J.

A summary of the article is shown below:

Intrinsic chemoresistance is the main reason for the failure of human pancreatic ductal adenocarcinoma (PDAC) therapy. To identify the candidate protein, we compared the protein expression profiling of PDAC cells and its distinct surviving cells following primary treatment with gemcitabine (GEM) and 5-fluorouracil (5-FU) by two-dimensional electrophoresis combined with liquid chromatography-mass spectrometry or mass spectrometry. A total of 20 differentially expressed proteins were identified, and annexin A1 (ANXA1) was analyzed for further validation. The functional validation showed that the downregulation of ANXA1 contributes to GEM and 5-FU resistance in PDAC cells through protein kinase C/c-Jun N-terminal kinase/P-glycoprotein signaling pathway. Our findings provide a platform for the further elucidation of the underlying mechanisms of PDAC intrinsic chemoresistance and demonstrated that ANXA1 may be a valid marker for anticancer drug development.

Check out the article’s website on Pubmed for more information:



This article is a good source of information and a good way to become familiar with topics such as: ANXA1; Intrinsic chemoresistance; Pancreatic ductal adenocarcinoma; Two dimensional electrophoresis.